Regulatory approval

Published by the Health Canada. Approved

Health Canada approved brigatinib as monotherapy for the first-line treatment of adult patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.

This is written in the approval document as:

ALUNBRIG (brigatinib) is indicated as a monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).

Citation

Takeda Canada Inc. Alunbrig (brigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00066731.PDF. Revised July 2022. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals